RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.79

Change

-0.29 (-2.42)%

Market Cap

N/A

Volume

6.10K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.96 (-2.09%)

USD 1.42B
PSQ ProShares Short QQQ

-1.16 (-2.83%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

-1.64 (-6.28%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

-4.02 (-17.40%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

-0.88 (-2.10%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

-2.15 (-3.73%)

USD 0.23B
RWM ProShares Short Russell2000

-0.43 (-2.00%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

-2.25 (-15.36%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

-0.23 (-1.93%)

USD 0.18B
DOG ProShares Short Dow30

-0.33 (-1.16%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.92% 51% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.92% 51% F 60% D-
Trailing 12 Months  
Capital Gain 2.89% 91% A- 56% F
Dividend Return 2.55% 60% D- 46% F
Total Return 5.44% 91% A- 52% F
Trailing 5 Years  
Capital Gain -57.96% 80% B- 7% C-
Dividend Return 3.12% 77% C+ 6% D-
Total Return -54.84% 80% B- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 66.40% 39% F 96% N/A
Dividend Return 67.84% 39% F 96% N/A
Total Return 1.44% 62% D 35% F
Risk Return Profile  
Volatility (Standard Deviation) 433.06% 63% D 3% F
Risk Adjusted Return 15.66% 54% F 33% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.